43 related articles for article (PubMed ID: 22715589)
1. The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.
Boddicker RL; Kip NS; Xing X; Zeng Y; Yang ZZ; Lee JH; Almada LL; Elsawa SF; Knudson RA; Law ME; Ketterling RP; Cunningham JM; Wu Y; Maurer MJ; O'Byrne MM; Cerhan JR; Slager SL; Link BK; Porcher JC; Grote DM; Jelinek DF; Dogan A; Ansell SM; Fernandez-Zapico ME; Feldman AL
Blood; 2015 May; 125(20):3118-27. PubMed ID: 25833963
[TBL] [Abstract][Full Text] [Related]
2. Analysis of NF-κB Pathway Proteins in Pediatric Hodgkin Lymphoma: Correlations with EBV Status and Clinical Outcome-A Children's Oncology Group Study.
Horton TM; Sheehan AM; López-Terrada D; Hutchison RE; Narendra S; Wu MF; Liu H
Lymphoma; 2012; 2012():. PubMed ID: 31406604
[TBL] [Abstract][Full Text] [Related]
3. Modulating inflammation through the negative regulation of NF-κB signaling.
Rothschild DE; McDaniel DK; Ringel-Scaia VM; Allen IC
J Leukoc Biol; 2018 Feb; ():. PubMed ID: 29389019
[TBL] [Abstract][Full Text] [Related]
4. The Opposite Functions of CD30 Ligand Isoforms.
Printsev I; Alalli E; Bilsborough J
Curr Issues Mol Biol; 2024 Mar; 46(3):2741-2756. PubMed ID: 38534788
[TBL] [Abstract][Full Text] [Related]
5. CD30 induces Reed-Sternberg cell-like morphology and chromosomal instability in classic Hodgkin lymphoma cell lines.
Watanabe M; Hatsuse H; Nagao K; Nakashima M; Uchimaru K; Otsu M; Miyazaki K; Horie R
Cancer Sci; 2023 Aug; 114(8):3433-3445. PubMed ID: 37302818
[TBL] [Abstract][Full Text] [Related]
6. Multi-targeted immunotherapeutics to treat B cell malignancies.
Gambles MT; Yang J; Kopeček J
J Control Release; 2023 Jun; 358():232-258. PubMed ID: 37121515
[TBL] [Abstract][Full Text] [Related]
7. A novel anti-membrane CD30 single-chain variable fragment discovered from the human phage library: A potential targeted immunotherapy.
Chanpong T; Seesuay W; Chiangjong W; Jiramornimit P; Preedagasamzin S; Atjanasuppat K; Jittorntrum B; Prasongtanakij S; Tawinwung S; Pukiat S; Saisawang C; Borwornpinyo S; Sa-Ngiamsuntorn K; Chaichumpa W; Hongeng S; Anurathapan U
PLoS One; 2023; 18(4):e0284708. PubMed ID: 37079526
[TBL] [Abstract][Full Text] [Related]
8. AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL.
Wu Z; Nicoll M; Ingham RJ
Exp Hematol Oncol; 2021 Jan; 10(1):4. PubMed ID: 33413671
[TBL] [Abstract][Full Text] [Related]
9. The c-Jun and JunB transcription factors facilitate the transit of classical Hodgkin lymphoma tumour cells through G
Zhang J; Wu Z; Savin A; Yang M; Hsu YR; Jantuan E; Bacani JTC; Ingham RJ
Sci Rep; 2018 Oct; 8(1):16019. PubMed ID: 30375407
[TBL] [Abstract][Full Text] [Related]
10. Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma.
Renner C; Stenner F
Front Oncol; 2018; 8():193. PubMed ID: 29915720
[TBL] [Abstract][Full Text] [Related]
11. The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.
Garces de Los Fayos Alonso I; Liang HC; Turner SD; Lagger S; Merkel O; Kenner L
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29597249
[TBL] [Abstract][Full Text] [Related]
12. Targeting Hodgkin and Reed-Sternberg Cells with an Inhibitor of Heat-Shock Protein 90: Molecular Pathways of Response and Potential Mechanisms of Resistance.
Segges P; Corrêa S; Du Rocher B; Vera-Lozada G; Krsticevic F; Arce D; Sternberg C; Abdelhay E; Hassan R
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29534015
[TBL] [Abstract][Full Text] [Related]
13. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.
van der Weyden CA; Pileri SA; Feldman AL; Whisstock J; Prince HM
Blood Cancer J; 2017 Sep; 7(9):e603. PubMed ID: 28885612
[TBL] [Abstract][Full Text] [Related]
14. TRAF2 recruitment via T61 in CD30 drives NFκB activation and enhances hESC survival and proliferation.
Thakar NY; Ovchinnikov DA; Hastie ML; Kobe B; Gorman JJ; Wolvetang EJ
Mol Biol Cell; 2015 Mar; 26(5):993-1006. PubMed ID: 25568342
[TBL] [Abstract][Full Text] [Related]
15. Expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) in tumor cells.
Staege MS; Müller K; Kewitz S; Volkmer I; Mauz-Körholz C; Bernig T; Körholz D
PLoS One; 2014; 9(2):e89577. PubMed ID: 24651368
[TBL] [Abstract][Full Text] [Related]
16. Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
Watanabe M; Itoh K; Togano T; Kadin ME; Watanabe T; Higashihara M; Horie R
Am J Pathol; 2012 Feb; 180(2):831-8. PubMed ID: 22107829
[TBL] [Abstract][Full Text] [Related]
17. Targeted repression of overexpressed CD30 downregulates NF-kappaB and ERK1/2 pathway in Hodgkin lymphoma cell lines.
Watanabe M; Nakano K; Togano T; Nakashima M; Higashihara M; Kadin ME; Watanabe T; Horie R
Oncol Res; 2011; 19(10-11):463-9. PubMed ID: 22715589
[TBL] [Abstract][Full Text] [Related]
18. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma.
Watanabe M; Sasaki M; Itoh K; Higashihara M; Umezawa K; Kadin ME; Abraham LJ; Watanabe T; Horie R
Cancer Res; 2005 Sep; 65(17):7628-34. PubMed ID: 16140928
[TBL] [Abstract][Full Text] [Related]
19. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells.
Wright CW; Rumble JM; Duckett CS
J Biol Chem; 2007 Apr; 282(14):10252-62. PubMed ID: 17261581
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
